{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T23:45:06Z","timestamp":1780789506049,"version":"3.54.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jaad.2025.01.069","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T18:04:05Z","timestamp":1738346645000},"page":"1327-1336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Nail toxicity associated with anticancer agents"],"prefix":"10.1016","volume":"92","author":[{"given":"Eden N.","family":"Axler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Iorizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"McLellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5913-9304","authenticated-orcid":false,"given":"Shari R.","family":"Lipner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2025.01.069_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA A Cancer J Clin"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.069_bib2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.det.2007.01.006","article-title":"Drug reactions affecting the nail unit: diagnosis and management","volume":"25","author":"Piraccini","year":"2007","journal-title":"Dermatol Clin"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.069_bib3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.det.2006.03.004","article-title":"Drug-induced nail diseases","volume":"24","author":"Piraccini","year":"2006","journal-title":"Dermatol Clin"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2025.01.069_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.069_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4103\/ijd.ijd_723_22","article-title":"Impact of chemotherapy-induced nail changes on quality of life: a cross-sectional study from a tertiary care centre","volume":"69","author":"Trivedi","year":"2024","journal-title":"Indian J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.069_bib6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1078155208100450","article-title":"Nail toxicity induced by cancer chemotherapy","volume":"15","author":"Gilbar","year":"2009","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.069_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.det.2007.08.003","article-title":"Malignancy and cancer treatment-related hair and nail changes","volume":"26","author":"Hinds","year":"2008","journal-title":"Dermatol Clin"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.069_bib8","article-title":"Narrative review of drug-associated nail toxicities in oncologic patients","volume":"13","author":"Emvalomati","year":"2023","journal-title":"Dermatol Pract Concept"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.069_bib9","doi-asserted-by":"crossref","first-page":"953","DOI":"10.4103\/idoj.IDOJ_84_20","article-title":"Nail changes caused by chemotherapy among cancer patients: a cross-sectional study of northwest Rajasthan","volume":"11","author":"Trivedi","year":"2020","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.jaad.2025.01.069_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-218644","article-title":"Longitudinal melanonychia on multiple nails induced by hydroxyurea","volume":"2017","author":"Nguyen","year":"2017","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.069_bib11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1067\/mjd.2002.120910","article-title":"Nail pigmentation caused by hydroxyurea: report of 9 cases","volume":"47","author":"Aste","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.069_bib12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000351874","article-title":"Chromonychia secondary to chemotherapy","volume":"5","author":"Lopes","year":"2013","journal-title":"Case Rep Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.069_bib13","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1111\/pde.13721","article-title":"Transverse melanonychia in a child receiving chemotherapy","volume":"36","author":"Stephens","year":"2019","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.069_bib14","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jaad.2022.06.1165","article-title":"Clinical and dermoscopic findings of benign longitudinal melanonychia due to melanocytic activation differ by skin type and predict likelihood of nail matrix biopsy","volume":"87","author":"Lee","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.069_bib15","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/S1470-2045(14)71133-7","article-title":"Nail toxicities induced by systemic anticancer treatments","volume":"16","author":"Robert","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.069_bib16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management","volume":"71","author":"Miller","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.069_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40257-022-00671-6","article-title":"Leukonychia: what can white nails tell us?","volume":"23","author":"Iorizzo","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.069_bib18","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1046\/j.1365-4362.2003.01727.x","article-title":"Chemotherapy induced transverse leukonychia in children","volume":"42","author":"Yoruk","year":"2003","journal-title":"Int J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2025.01.069_bib19","first-page":"865","article-title":"Chemotherapy induced transverse leukonychia (Mees lines)","volume":"44","author":"Parakh","year":"2007","journal-title":"Indian Pediatr"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.069_bib20","doi-asserted-by":"crossref","first-page":"E149","DOI":"10.1503\/cmaj.090501","article-title":"Mees lines and Beau lines after chemotherapy","volume":"182","author":"Huang","year":"2010","journal-title":"CMAJ"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.069_bib21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00002018-199921030-00004","article-title":"Drug-induced nail disorders: incidence, management and prognosis","volume":"21","author":"Piraccini","year":"1999","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.069_bib22","first-page":"OD04","article-title":"Cyclophosphamide and doxorubicin induced melanonychia: a case report","volume":"11","author":"Prajapati","year":"2017","journal-title":"J Clin Diagn Res"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.069_bib23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/jid.1951.73","article-title":"Hereditary leuconychia totalis","volume":"17","author":"Kruse","year":"1951","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.069_bib24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1684\/ejd.2016.2747","article-title":"Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma","volume":"26","author":"Dika","year":"2016","journal-title":"Eur J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.069_bib25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1468-3083.2004.00775.x","article-title":"Drugs and nails","volume":"18","author":"Uyttendaele","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.069_bib26","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamadermatol.2016.0225","article-title":"Hair and nail changes during long-term therapy with ibrutinib for chronic lymphocytic leukemia","volume":"152","author":"Bitar","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.069_bib46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13555-019-00338-x","article-title":"Pathogenesis, clinical signs and treatment recommendations in brittle nails: a review","volume":"10","author":"Chessa","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2025.01.069_bib27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1752-1947-2-24","article-title":"Nail changes secondary to docetaxel chemotherapy : a case report","volume":"2","author":"Ghafoor","year":"2008","journal-title":"J Med Case Rep"},{"issue":"7","key":"10.1016\/j.jaad.2025.01.069_bib28","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1111\/j.1365-2230.2009.03275.x","article-title":"Improvement in docetaxel-induced nail changes associated with cyclooxygenase-2 inhibitor treatment","volume":"34","author":"Nakamura","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.069_bib29","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.tjog.2019.07.023","article-title":"Paclitaxel-related nail toxicity","volume":"58","author":"Yang","year":"2019","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.069_bib30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.det.2014.12.001","article-title":"Tips to treat the 5 most common nail disorders: brittle nails, onycholysis, paronychia, psoriasis, onychomycosis","volume":"33","author":"Iorizzo","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2025.01.069_bib31","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.2147\/DDDT.S139643","article-title":"Onychomadesis associated with chemotherapy: case report and mini literature review","volume":"11","author":"Li","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"12","key":"10.1016\/j.jaad.2025.01.069_bib32","doi-asserted-by":"crossref","DOI":"10.5070\/D32612051366","article-title":"Lichenoid drug eruption after treatment with ixekizumab for plaque psoriasis","volume":"26","author":"Ghiam","year":"2020","journal-title":"Dermatol Online J"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.069_bib33","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.jaad.2019.09.060","article-title":"Intralesional triamcinolone matrix injections for treatment of trachyonychia","volume":"82","author":"Gupta","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.069_bib34","doi-asserted-by":"crossref","first-page":"640","DOI":"10.4103\/0378-6323.86470","article-title":"Trachyonychia: a comprehensive review","volume":"77","author":"Gordon","year":"2011","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.069_bib35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2340\/00015555-0758","article-title":"Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature","volume":"90","author":"Kuraishi","year":"2010","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"10.1016\/j.jaad.2025.01.069_bib36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5070\/D319T833JH","article-title":"Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: report of a case and literature review","volume":"14","author":"Wahiduzzaman","year":"2008","journal-title":"Dermatol Online J"},{"issue":"3-4","key":"10.1016\/j.jaad.2025.01.069_bib37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000449063","article-title":"Trachyonychia: review and update on clinical aspects, histology, and therapy","volume":"2","author":"Haber","year":"2017","journal-title":"Skin Appendage Disord"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.069_bib38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jaad.2022.02.030","article-title":"Treatment of immune checkpoint inhibitor-mediated psoriasis: a systematic review","volume":"87","author":"Said","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.01.069_bib39","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.069_bib40","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1080\/09546634.2021.1927950","article-title":"Red light emitting diode as an adjuvant treatment for epidermal growth factor receptor inhibitors-induced paronychia","volume":"33","author":"Jornsamer","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.069_bib41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.abd.2021.05.007","article-title":"Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital","volume":"97","author":"Ceglio","year":"2022","journal-title":"An Bras Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.01.069_bib42","first-page":"2341","article-title":"Are topical beta-blockers really effective \"in real life\" for targeted therapy-induced paronychia","volume":"27","author":"Sibaud","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2025.01.069_bib43","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212613","article-title":"Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature","volume":"8","author":"Sollena","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.jaad.2025.01.069_bib44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000335632","article-title":"Cutaneous drug eruptions associated with the use of new oncological drugs","volume":"97","author":"Belloni","year":"2012","journal-title":"Chem Immunol Allergy"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.069_bib45","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr Drug Metab"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.069_bib47","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejon.2011.06.007","article-title":"Taxane-induced nail changes: predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity","volume":"16","author":"Can","year":"2012","journal-title":"Eur J Oncol Nurs"},{"issue":"10","key":"10.1016\/j.jaad.2025.01.069_bib48","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/(SICI)1097-0142(20000515)88:10<2367::AID-CNCR22>3.0.CO;2-#","article-title":"Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature","volume":"88","author":"Hussain","year":"2000","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.069_bib49","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1684\/ejd.2016.2833","article-title":"Dermatological adverse events with taxane chemotherapy","volume":"26","author":"Sibaud","year":"2016","journal-title":"Eur J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.069_bib50","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1046\/j.1468-3083.2003.00774.x","article-title":"Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel)","volume":"17","author":"Ghetti","year":"2003","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.069_bib51","doi-asserted-by":"crossref","first-page":"514","DOI":"10.5021\/ad.2014.26.4.514","article-title":"Green nail syndrome treated with the application of tobramycin eye drop","volume":"26","author":"Bae","year":"2014","journal-title":"Ann Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.01.069_bib52","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/0284186X.2017.1420912","article-title":"PATEO syndrome: periarticular thenar erythema with onycholysis","volume":"57","author":"Rzepecki","year":"2018","journal-title":"Acta Oncol"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.069_bib53","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/01.coc.0000026486.56886.18","article-title":"Cutaneous hand and foot toxicity associated with cancer chemotherapy","volume":"26","author":"Childress","year":"2003","journal-title":"Am J Clin Oncol"},{"issue":"19","key":"10.1016\/j.jaad.2025.01.069_bib55","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1200\/JCO.2005.15.651","article-title":"Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand","volume":"23","author":"Scott\u00e9","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.069_bib56","article-title":"Prophylactic management for taxane-induced nail toxicity: a systematic review and meta-analysis","volume":"28","author":"Huang","year":"2019","journal-title":"Eur J Cancer Care"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.069_bib57","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/annonc\/mdg050","article-title":"Taxane-induced nail changes: incidence, clinical presentation and outcome","volume":"14","author":"Minisini","year":"2003","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.069_bib58","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/MAJ.0000000000000244","article-title":"Beau's lines of the fingernails","volume":"349","author":"Ryu","year":"2015","journal-title":"Am J Med Sci"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.069_bib59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.kjms.2017.09.008","article-title":"Beau's lines in nails: an indicator of recent Docetaxel and 5-FU use","volume":"34","author":"Chu","year":"2018","journal-title":"Kaohsiung J Med Sci"},{"issue":"7","key":"10.1016\/j.jaad.2025.01.069_bib60","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-4362.1989.tb02507.x","article-title":"Possible carbamazepine-induced reversible onychomadesis","volume":"28","author":"Mishra","year":"1989","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.069_bib61","doi-asserted-by":"crossref","first-page":"464.e2","DOI":"10.12809\/hkmj134084","article-title":"Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate","volume":"20","author":"Lau","year":"2014","journal-title":"Hong Kong Med J"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.069_bib62","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1468-3083.2006.01887.x","article-title":"Nail changes associated with chemotherapy in children","volume":"21","author":"Chen","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1-2","key":"10.1016\/j.jaad.2025.01.069_bib63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000445544","article-title":"Trachyonychia and twenty-nail dystrophy: a comprehensive review and discussion of diagnostic accuracy","volume":"2","author":"Jacobsen","year":"2016","journal-title":"Skin Appendage Disord"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.069_bib64","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaad.2021.07.022","article-title":"Treatment recommendations for nail unit toxicities secondary to targeted cancer therapy based on collective experience and evidence-based literature review","volume":"87","author":"Wetzel","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.069_bib65","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jaad.2020.02.056","article-title":"Isolated nail lichen planus: an expert consensus on treatment of the classical form","volume":"83","author":"Iorizzo","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.069_bib66","first-page":"909","article-title":"Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors","volume":"20","author":"Peuvrel","year":"2012","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.069_bib67","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.soncn.2014.05.003","article-title":"Non-rash dermatologic adverse events related to targeted therapies","volume":"30","author":"Bryce","year":"2014","journal-title":"Semin Oncol Nurs"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.069_bib68","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4103\/0378-6323.159950","article-title":"Dermatological adverse reactions to cancer chemotherapy","volume":"81","author":"Pavey","year":"2015","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"10.1016\/j.jaad.2025.01.069_bib69","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/ijd.15740","article-title":"Review of chemotherapy-associated paronychia","volume":"61","author":"Gupta","year":"2022","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.069_bib70","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2230.2012.04358.x","article-title":"Gutter method: noninvasive management of ingrown nails caused by epidermal growth factor inhibitor treatment","volume":"37","author":"Harada","year":"2012","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.069_bib71","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2006.09.005","article-title":"Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management","volume":"56","author":"Hu","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.069_bib72","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaad.2006.09.013","article-title":"Nail toxicity associated with epidermal growth factor receptor inhibitor therapy","volume":"56","author":"Fox","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.01.069_bib73","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/jdv.15121","article-title":"Using a novel scoring system for paronychia related to oncologic treatments (SPOT) for assessing paronychia severity and its correlation with pain index and quality of life","volume":"33","author":"Ho","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.069_bib74","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4103\/idoj.IDOJ_133_18","article-title":"Systemic drug-induced chronic paronychia and periungual pyogenic granuloma","volume":"9","author":"Wollina","year":"2018","journal-title":"Indian Dermatol Online J"},{"issue":"5","key":"10.1016\/j.jaad.2025.01.069_bib75","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1365-2133.2010.09906.x","article-title":"Periungual and subungual pyogenic granuloma","volume":"163","author":"Piraccini","year":"2010","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.01.069_bib76","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2025.01.069_bib77","series-title":"StatPearls","article-title":"Subungual hematoma drainage","author":"Pingel","year":"2023"},{"issue":"9","key":"10.1016\/j.jaad.2025.01.069_bib78","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.1986.4.9.1405","article-title":"Vascular toxicity associated with antineoplastic agents","volume":"4","author":"Doll","year":"1986","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jaad.2025.01.069_bib79","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/1097-0142(19900115)65:2<303::AID-CNCR2820650220>3.0.CO;2-L","article-title":"Capillary microscopy is a potentially useful method for detecting bleomycin vascular toxicity","volume":"65","author":"Bellmunt","year":"1990","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.jaad.2025.01.069_bib80","doi-asserted-by":"crossref","first-page":"658","DOI":"10.12968\/hmed.2019.80.11.658","article-title":"Raynaud's phenomenon","volume":"80","author":"Devgire","year":"2019","journal-title":"Br J Hosp Med (Lond)"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.069_bib81","doi-asserted-by":"crossref","first-page":"288","DOI":"10.7326\/0003-4819-95-3-288","article-title":"Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer","volume":"95","author":"Vogelzang","year":"1981","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.069_bib82","doi-asserted-by":"crossref","first-page":"580","DOI":"10.7861\/clinmed.2020-0754","article-title":"Raynaud's phenomenon","volume":"20","author":"Haque","year":"2020","journal-title":"Clin Med (Lond)"},{"issue":"6","key":"10.1016\/j.jaad.2025.01.069_bib83","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/SAP.0000000000000614","article-title":"Digital sympathectomy in patients with scleroderma: an overview of the Practice and referral patterns and perceptions of rheumatologists","volume":"75","author":"Chiou","year":"2015","journal-title":"Ann Plast Surg"},{"issue":"3","key":"10.1016\/j.jaad.2025.01.069_bib84","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/09546630701657187","article-title":"Review of antifungal therapy, part II: treatment rationale, including specific patient populations","volume":"19","author":"Baran","year":"2008","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"10.1016\/j.jaad.2025.01.069_bib85","first-page":"1076","article-title":"Therapeutic recommendations for the treatment of toenail onychomycosis in the US","volume":"20","author":"Lipner","year":"2021","journal-title":"J Drugs Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225001562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225001562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:02:50Z","timestamp":1777568570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225001562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0190962225001562"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.01.069","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nail toxicity associated with anticancer agents","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.01.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}